Gabelli lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a sell rating in a report published on Wednesday morning, MarketBeat.com reports.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $6.50 price target on the stock in a report on Thursday, January 24th. Citigroup reissued a buy rating and issued a $14.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, January 22nd. They noted that the move was a valuation call. BidaskClub raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, January 17th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, January 25th. Finally, Wedbush set a $36.00 price objective on shares of Lexicon Pharmaceuticals and gave the stock an outperform rating in a research report on Tuesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $20.38.

Shares of Lexicon Pharmaceuticals stock opened at $7.41 on Wednesday. Lexicon Pharmaceuticals has a 12-month low of $4.26 and a 12-month high of $13.97. The stock has a market capitalization of $784.90 million, a PE ratio of -5.83 and a beta of 0.70.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $13.33 million. During the same period in the prior year, the firm posted ($0.27) earnings per share. The company’s revenue for the quarter was down 49.7% on a year-over-year basis. As a group, research analysts predict that Lexicon Pharmaceuticals will post -1.28 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Pegasus Asset Management Inc. bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $66,000. Paloma Partners Management Co bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $73,000. CWM Advisors LLC increased its position in shares of Lexicon Pharmaceuticals by 30.2% in the fourth quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 3,030 shares during the last quarter. D.A. Davidson & CO. bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $87,000. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Lexicon Pharmaceuticals by 409.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 11,862 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Day Trading

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.